Моксонідин (Ukrainian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Моксонідин" in Ukrainian language version.

refsWebsite

Global rank Ukrainian rank

6nih.gov

4^th place

5^th place

5doi.org

2^nd place

4^th place

1gp2u.com.au

low place

1aspetjournals.org

6,663^rd place

6,498^th place

aspetjournals.org

jpet.aspetjournals.org

Fairbanks CA, Wilcox GL (July 1999). Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 403—412. PMID 10381806.

doi.org

Weimann HJ, Rudolph M (1992). Clinical Pharmacokinetics of Moxonidine. Journal of Cardiovascular Pharmacology. 20 (Suppl. 4): S37—S41. doi:10.1097/00005344-199220004-00008.
Fenton C, Keating GM, Lyseng-Williamson KA (2006). Moxonidine: a review of its use in essential hypertension. Drugs. 66 (4): 477—496. doi:10.2165/00003495-200666040-00006. PMID 16597164.
Bamberger CM, Mönig H, Mill G, Gödde E, Schulte HM (1995). Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH. Experimental and Clinical Endocrinology & Diabetes. 103 (3): 205—208. doi:10.1055/s-0029-1211351. PMID 7584524.
Frei M, Küster L, Gardosch von Krosigk PP, Koch HF, Küppers H (1994). Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. Journal of Cardiovascular Pharmacology. 24 (Suppl 1): S25—S28. doi:10.1097/00005344-199424001-00005. PMID 7533223.
Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ (October 2003). Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). European Journal of Heart Failure. 5 (5): 659—667. doi:10.1016/S1388-9842(03)00163-6. PMID 14607206. {{cite journal}}: Недійсний |displayauthors=6 (довідка)

gp2u.com.au

Physiotens Tablets (moxonidine) Product Information (PDF). Abbott Australasia Pty Ltd, 32-34 Lord Street, Botany NSW 2019, Australia. Процитовано 1 вересня 2016.

nih.gov

pubmed.ncbi.nlm.nih.gov

Fenton C, Keating GM, Lyseng-Williamson KA (2006). Moxonidine: a review of its use in essential hypertension. Drugs. 66 (4): 477—496. doi:10.2165/00003495-200666040-00006. PMID 16597164.
Fairbanks CA, Wilcox GL (July 1999). Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 403—412. PMID 10381806.
Bamberger CM, Mönig H, Mill G, Gödde E, Schulte HM (1995). Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH. Experimental and Clinical Endocrinology & Diabetes. 103 (3): 205—208. doi:10.1055/s-0029-1211351. PMID 7584524.
Prichard BN, Owens CW, Graham BR (August 1997). Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. Journal of Human Hypertension. 11 (Suppl 1): S29—S45. PMID 9321737.
Frei M, Küster L, Gardosch von Krosigk PP, Koch HF, Küppers H (1994). Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. Journal of Cardiovascular Pharmacology. 24 (Suppl 1): S25—S28. doi:10.1097/00005344-199424001-00005. PMID 7533223.
Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ (October 2003). Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). European Journal of Heart Failure. 5 (5): 659—667. doi:10.1016/S1388-9842(03)00163-6. PMID 14607206. {{cite journal}}: Недійсний |displayauthors=6 (довідка)